MeSH D009080 - mucocutaneous lymph node syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| CSL Behring | Human normal immunoglobulin | Privigen | 2008-04-24 | |||
| Grifols | Human normal immunoglobulin | Flebogamma DIF (previously Flebogammadif) | 2007-07-23 | |||
| Takeda | Human normal immunoglobulin | Kiovig | 2006-01-18 |
Clinical Trials
Historical Success Rate
Phase 1
100%7/7
Phase 2
36%4/11
Phase 3
18%2/11
Approved: 0Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use